IONS Q4 2023 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$13B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$325M+113.6% YoY

Gross Profit

$321M99.1% margin

Operating Income

-$6M-1.9% margin

Net Income

-$9M-2.9% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+125.0%

Cash Flow

Operating Cash Flow

$33M

Free Cash Flow

$34M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$3.0B

Total Liabilities

$2.6B

Stockholders' Equity

$387M

Cash & Equivalents

$399M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$325M	$152M	+113.6%
Gross Profit	$321M	$148M	+116.9%
Operating Income	-$6M	-$208M	+97.1%
Net Income	-$9M	-$52M	+82.3%

Revenue Segments

Research and Development Revenue

$246M36%

Collaborative Agreement Revenue

$179M26%

SPINRAZA Royalties

$112M16%

Commercial

$79M12%

Other Commercial

$34M5%

Product

$20M3%

Licensing and Other Royalties

$14M2%